Quote:

---

I know of some astute sciece based investors expecting fro 60 to an 80% improvement from the Standard of Care (SOC)

the tragedy here is that 60-80% improvement (or better because of IV infusion instead of subcutaneous) is what we will likely get from brazil trials, as that is what we got from the subgroup in our CD12 trial - and the FDA chose to overlook that.

some real sense of emergency is lost at the FDA.

its like the titanic is sinking and the crew wont let us use the lifeboats because they were painted that day and they arent dry yet. insufferable jackholes.

the real tragedy is drugs get approved all the time for 6-8% improvement of whatever standard of care there is at the time. everyday.

---